Búsqueda | Biblioteca Virtual en Salud Odontología. Uruguay

1.

Association of patient, treatment and disease characteristics with patient-reported outcomes: Results of the ECHO Registry.

Hay, Charles R M; Makris, Michael; Shima, Midori; Nagao, Azusa; Jiménez-Yuste, Víctor; Skinner, Mark; Kessler, Craig M; von Mackensen, Sylvia.

Haemophilia ; 30(1): 106-115, 2024 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-38030962

2.

Force-sensing treadmill gait analysis system can detect gait abnormalities in haemophilia patients without arthropathy.

Mawarikado, Yuya; Sakata, Asuka; Inagaki, Yusuke; Harada, Suguru; Tatsumi, Kohei; Matsumoto, Naoki; Ogiwara, Kenichi; Yada, Koji; Yoshimura, Yasushi; Kido, Akira; Tanaka, Yasuhito; Shima, Midori; Nogami, Keiji.

Haemophilia ; 30(3): 780-790, 2024 May.

Artículo en Inglés | MEDLINE | ID: mdl-38507270

3.

Longitudinal association between frequency of Internet use and incident disability among community-dwelling older people during the COVID-19 pandemic.

Tomioka, Kimiko; Shima, Midori; Saeki, Keigo.

Environ Health Prev Med ; 29: 13, 2024.

Artículo en Inglés | MEDLINE | ID: mdl-38447990

4.

Current and future therapies for haemophilia-Beyond factor replacement therapies.

Nogami, Keiji; Shima, Midori.

Br J Haematol ; 200(1): 23-34, 2023 01.

Artículo en Inglés | MEDLINE | ID: mdl-35869698

5.

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.

Callaghan, Michael U; Negrier, Claude; Paz-Priel, Ido; Chang, Tiffany; Chebon, Sammy; Lehle, Michaela; Mahlangu, Johnny; Young, Guy; Kruse-Jarres, Rebecca; Mancuso, Maria Elisa; Niggli, Markus; Howard, Monet; Bienz, Nives Selak; Shima, Midori; Jiménez-Yuste, Victor; Schmitt, Christophe; Asikanius, Elina; Levy, Gallia G; Pipe, Steven W; Oldenburg, Johannes.

Blood ; 137(16): 2231-2242, 2021 04 22.

Artículo en Inglés | MEDLINE | ID: mdl-33512413

6.

Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders.

Shima, Midori.

Ann Hematol ; 2023 Jun 30.

Artículo en Inglés | MEDLINE | ID: mdl-37391649

7.

Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab.

Ogiwara, Kenichi; Furukawa, Shoko; Shinohara, Sho; Tabuchi, Yuka; Arai, Nobuo; Noguchi-Sasaki, Mariko; Soeda, Tetsuhiro; Shima, Midori; Nogami, Keiji.

Haemophilia ; 29(1): 329-335, 2023 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-36137299

8.

The use of infrared thermography for non-invasive detection of bleeding and musculoskeletal abnormalities in patients with hemophilia: an observational study.

Kawasaki, Ryohei; Sakata, Asuka; Hosoda, Chihiro; Harada, Suguru; Soeda, Tetsuhiro; Nishida, Yukiko; Matsumoto, Naoki; Tatsumi, Kohei; Nogami, Keiji; Yoshimura, Yasushi; Shima, Midori.

Thromb J ; 21(1): 70, 2023 Jun 28.

Artículo en Inglés | MEDLINE | ID: mdl-37381012

9.

An ecological association of number of civil servants and physicians with prefectural-level rapid COVID-19 vaccination of older people in Japan.

Tomioka, Kimiko; Shima, Midori; Saeki, Keigo.

Environ Health Prev Med ; 28: 21, 2023.

Artículo en Inglés | MEDLINE | ID: mdl-37032066

10.

Emicizumab enhances thrombus formation in vitro under high shear flow conditions in whole blood from patients with type 1 and type 3 von Willebrand disease.

Yaoi, Hiroaki; Shida, Yasuaki; Ogiwara, Kenichi; Kitazawa, Takehisa; Shima, Midori; Nogami, Keiji.

Haemophilia ; 28(5): 694-701, 2022 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-35478475

11.

Clinical conditions and risk factors for inhibitor-development in patients with haemophilia: A decade-long prospective cohort study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2).

Nogami, Keiji; Taki, Masashi; Matsushita, Tadashi; Kojima, Tetsuhito; Oka, Toshiaki; Ohga, Shouichi; Kawakami, Kiyoshi; Sakai, Michio; Suzuki, Takashi; Higasa, Satoshi; Horikoshi, Yasuo; Shinozawa, Keiko; Tamura, Shogo; Yada, Koji; Imaizumi, Masue; Ohtsuka, Yoshitoshi; Iwasaki, Fuminori; Kobayashi, Masao; Takamatsu, Junki; Takedani, Hideyuki; Nakadate, Hisaya; Matsuo, Yoko; Matsumoto, Takeshi; Fujii, Teruhisa; Fukutake, Katsuyuki; Shirahata, Akira; Yoshioka, Akira; Shima, Midori.

Haemophilia ; 28(5): 745-759, 2022 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-35689832

12.

Heterogeneous coagulant potential of emicizumab in neonatal factor VIII-deficient plasma.

Takeyama, Masahiro; Furukawa, Shoko; Onishi, Tomoko; Noguchi-Sasaki, Mariko; Shima, Midori; Nogami, Keiji.

Pediatr Blood Cancer ; 69(7): e29731, 2022 07.

Artículo en Inglés | MEDLINE | ID: mdl-35441786

13.

Number of public health nurses and COVID-19 incidence rate by variant type: an ecological study of 47 prefectures in Japan.

Tomioka, Kimiko; Shima, Midori; Saeki, Keigo.

Environ Health Prev Med ; 27: 18, 2022.

Artículo en Inglés | MEDLINE | ID: mdl-35527010

14.

Age differences in the association of physical leisure activities with incident disability among community-dwelling older adults.

Tomioka, Kimiko; Shima, Midori; Saeki, Keigo.

Environ Health Prev Med ; 27: 16, 2022.

Artículo en Inglés | MEDLINE | ID: mdl-35354710

15.

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.

Mahlangu, Johnny; Oldenburg, Johannes; Paz-Priel, Ido; Negrier, Claude; Niggli, Markus; Mancuso, M Elisa; Schmitt, Christophe; Jiménez-Yuste, Victor; Kempton, Christine; Dhalluin, Christophe; Callaghan, Michael U; Bujan, Willem; Shima, Midori; Adamkewicz, Joanne I; Asikanius, Elina; Levy, Gallia G; Kruse-Jarres, Rebecca.

N Engl J Med ; 379(9): 811-822, 2018 08 30.

Artículo en Inglés | MEDLINE | ID: mdl-30157389

16.

New therapies using nonfactor products for patients with hemophilia and inhibitors.

Nogami, Keiji; Shima, Midori.

Blood ; 133(5): 399-406, 2019 01 31.

Artículo en Inglés | MEDLINE | ID: mdl-30559263

17.

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.

Young, Guy; Liesner, Ri; Chang, Tiffany; Sidonio, Robert; Oldenburg, Johannes; Jiménez-Yuste, Victor; Mahlangu, Johnny; Kruse-Jarres, Rebecca; Wang, Michael; Uguen, Marianne; Doral, Michelle Y; Wright, Lilyan Y; Schmitt, Christophe; Levy, Gallia G; Shima, Midori; Mancuso, Maria Elisa.

Blood ; 134(24): 2127-2138, 2019 12 12.

Artículo en Inglés | MEDLINE | ID: mdl-31697801

18.

Substitution therapy.

Shima, Midori; Sidonio, Robert F.

Haemophilia ; 27 Suppl 3: 53-59, 2021 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-32558019

19.

Emicizumab improves thrombus formation of type 2A von willebrand disease under high shear condition.

Yaoi, Hiroaki; Shida, Yasuaki; Kitazawa, Takehisa; Shima, Midori; Nogami, Keiji.

Haemophilia ; 27(2): e194-e203, 2021 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-33555083

20.

Long-term safety and efficacy of emicizumab for up to 5.8 years and patients' perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A.

Shima, Midori; Nagao, Azusa; Taki, Masashi; Matsushita, Tadashi; Oshida, Koichi; Amano, Kagehiro; Nagami, Sayaka; Okada, Norihiro; Maisawa, Shingo; Nogami, Keiji.

Haemophilia ; 27(1): 81-89, 2021 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-33236410

Biblioteca Virtual en Salud Odontología. Uruguay

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Association of patient, treatment and disease characteristics with patient-reported outcomes: Results of the ECHO Registry.

Force-sensing treadmill gait analysis system can detect gait abnormalities in haemophilia patients without arthropathy.

Longitudinal association between frequency of Internet use and incident disability among community-dwelling older people during the COVID-19 pandemic.

Current and future therapies for haemophilia-Beyond factor replacement therapies.

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.

Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders.

Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab.

The use of infrared thermography for non-invasive detection of bleeding and musculoskeletal abnormalities in patients with hemophilia: an observational study.

An ecological association of number of civil servants and physicians with prefectural-level rapid COVID-19 vaccination of older people in Japan.

Emicizumab enhances thrombus formation in vitro under high shear flow conditions in whole blood from patients with type 1 and type 3 von Willebrand disease.

Clinical conditions and risk factors for inhibitor-development in patients with haemophilia: A decade-long prospective cohort study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2).

Heterogeneous coagulant potential of emicizumab in neonatal factor VIII-deficient plasma.

Number of public health nurses and COVID-19 incidence rate by variant type: an ecological study of 47 prefectures in Japan.

Age differences in the association of physical leisure activities with incident disability among community-dwelling older adults.

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.

New therapies using nonfactor products for patients with hemophilia and inhibitors.

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.

Substitution therapy.

Emicizumab improves thrombus formation of type 2A von willebrand disease under high shear condition.

Long-term safety and efficacy of emicizumab for up to 5.8 years and patients' perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A.